Ocugen is a biopharmaceutical company focused on gene and cell therapies, biologics, and vaccines to improve global health. Its pipeline includes a modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. Ocugen is developing OCU400, OCU410, and OCU410ST for inherited retinal diseases like retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, and multifactorial diseases such as dry age-related macular degeneration and geographic atrophy. Co. is working on an inhalation-based mucosal vaccine platform with OCU500 (COVID-19 vaccine), OCU510 (seasonal flu vaccine), and OCU520 (combination flu and COVID-19 vaccine). The OCGN YTD return is shown above.
The YTD Return on the OCGN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether OCGN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OCGN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|